Nektar posts mid-stage trial data for hair loss drug (NKTR)
Summary
Nektar Therapeutics (NKTR) stock rises as the company reports long-term data from a mid-stage trial for lead asset rezpegaldesleukin in alopecia areata. Read mo...
Description
Nektar Therapeutics (NKTR) stock rises as the company reports long-term data from a mid-stage trial for lead asset rezpegaldesleukin in alopecia areata. Read mo...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source